Early diagnosis and treatment of ankylosing spondylitis in Africa and the Middle East

Clinical Rheumatology

Volumn 31, Issue 11, 2012, Pages 1633-1639

  Rachid, Bahiri ^a   El Zorkany, Bassel ^b   Youseif, Ehab ^c   Tikly, Mohammed ^d  

^a Hopital El Ayachi   (Morocco)

^b CAIRO UNIVERSITY   (Egypt)

^c PFIZER INC   (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Africa; Ankylosing spondylitis; Diagnosis; HLA B27; Middle East

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT;

AFRICA; ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; CLINICAL FEATURE; DELAYED DIAGNOSIS; DISEASE SEVERITY; DISEASE SURVEILLANCE; EARLY DIAGNOSIS; ETHNIC DIFFERENCE; EXERCISE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENETICS; MIDDLE EAST; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SEX DIFFERENCE; SPINE RADIOGRAPHY;

ADULT; AFRICA; ANTI-INFLAMMATORY AGENTS; COST-BENEFIT ANALYSIS; EARLY DIAGNOSIS; FEMALE; HLA-B27 ANTIGEN; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MIDDLE EAST; PREVALENCE; RHEUMATOLOGY; RISK FACTORS; SPONDYLITIS, ANKYLOSING; TIME FACTORS;

EID: 84872171078     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-012-2058-5     Document Type: Article

References (52)

1. Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369:1379-1390
2. Zeidler H, Amor B (2011) The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress. Ann Rheum Dis 70:1-3
3. Rudwaleit M, Landewe R, van der Heijde D et al (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis 68:770-776
4. Rudwaleit M, van der Heijde D, Landewe R et al (2009) The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68:777-783
5. Dougados M (2005) Ankylosing spondylitis. Orphanet Encyclopedia http://www.orpha.net/data/patho/Pro/en/AnkylosingSpondylarthritis-FRenPro41.pdf. Accessed 2 April 2012
6. van der Linden SJ (2009) Ankylosing spondylitis. In: Firestein GS et al (eds) Kelley's textbook of rheumatology, 8th edn. Saunders Elsevier, Philadelphia, pp 1169-1189
7. Sieper J, Rudwaleit M (2005) Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care. Ann Rheum Dis 64:659-663
8. Sieper J, Rudwaleit M, Khan MA, Braun J (2006) Concepts and epidemiology of spondyloarthritis. Best Pract Res Clin Rheumatol 20:401-417
9. El Mansouri L, Bahiri R, Abourazzak FE, Abouqal R, Hajjaj-Hassouni N (2009) Two distinct patterns of ankylosing spondylitis in Moroccan patients. Rheumatol Int 29:1423-1429
10. al Attia HM, Sherif AM, Hossain MM, Ahmed YH (1998) The demographic and clinical spectrum of Arab versus Asian patients with ankylosing spondylitis in the UAE. Rheumatol Int 17:193-196
11. al-Arfaj A (1996) Profile of ankylosing spondylitis in Saudi Arabia. Clin Rheumatol 15:287-289
12. Al-Rawi ZS, Al-Shakarchi HA, Hasan F, Thewaini AJ (1978) Ankylosing spondylitis and its association with the histocompatibility antigen HLA-B27: an epidemiological and clinical study. Rheumatol Rehabil 17:72-75
13. Brown MA, Jepson A, Young A, Whittle HC, Greenwood BM, Wordsworth BP (1997) Ankylosing spondylitis inWest Africans - evidence for a non-HLA-B27 protective effect. Ann Rheum Dis 56:68-70
14. Chalmers IM (1980) Ankylosing spondylitis in African Blacks. Arthritis Rheum 23:1366-1370
15. Mijiyawa M (1993) Spondyloarthropathies in patients attending the rheumatology unit of Lomé Hospital. J Rheumatol 20:1167-1169
16. Ouédraogo DD, Tiéno H, Kaboré H, Palazzo E, Meyer O, Drabo JY (2009) Ankylosing spondylitis in rheumatology patients in Ouagadougou (Burkina Faso). Clin Rheumatol 28:1375-1377
17. Stein M, Davis P, Emmanuel J, West G (1990) The spondyloarthropathies in Zimbabwe: a clinical and immunogenetic profile. J Rheumatol 17:1337-1339
18. Belachew DA, Sandu N, Schaller B, Guta Z (2009) Ankylosing spondylitis in sub-Saharan Africa. Postgrad Med J 85:353-357
19. Mijiyawa M, Oniankitan O, Khan MA (2000) Spondyloarthropathies in sub-Saharan Africa. Curr Opin Rheumatol 12:281-286
20. Hajjaj N, Burgos Vargos R (2008) Ankylosing spondylitis and reactive arthritis in the developing world. Best Pract Res Clin Rheumatol 22:709-723
21. Hajjaj-Hassouni N, Maetzel A, Dougados M, Amor B (1993) A comparative study of patients evaluated for spondyloarthropathy in France and Morocco. Rev Rhum Engl Ed 60:341-346
22. Claudepierre P, Gueguen A, Ladjouze A et al (1995) Predictive factors of severity of spondyloarthropathy in North Africa. Br J Rheumatol 34:1139-1145
23. Njobvu P, McGill P, Kerr H, Jellis J, Pobee J (1998) Spondyloarthropathy and human immunodeficiency virus infection in Zambia. J Rheumatol 25:1553-1559
24. Lopez-Larrea C, Njobvu PD, Gonzalez S, Blanco-Gelaz MA, Martinez-Borra J, Lopez-Vazquez A (2005) The HLA-B*5703 allele confers susceptibility to the development of spondylarthropathies in Zambian human immunodeficiency virus-infected patients with slow progression to acquired immunodeficiency syndrome. Arthritis Rheum 52:275-279
25. O'Shea F, Salonen D, Inman R (2007) The challenge of early diagnosis in ankylosing spondylitis. J Rheumatol 34:5-7
26. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003) Age at disease onset and diagnosis delay in HLAB27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23:61-66
27. Mau W, Zeidler H, Mau R et al (1988) Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year follow-up. J Rheumatol 15:1109-1114
28. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361-368
29. Zochling J, Braun J (2007) Assessments in ankylosing spondylitis. Best Pract Res Clin Rheumatol 21:699-712
30. Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, Østergaard M, Lambert RG (2009) Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 60:93-102
31. Pradeep DJ, Keat A, Gaffney K (2008) Predicting outcome in ankylosing spondylitis. Rheumatology (Oxford) 47:942-945
32. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286-2291
33. Kchir MM, Hamdi W, Kochbati S et al (2009) Validation of the Tunisian versions of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Disease Activity Index (BASDAI). Tunis Med 87:527-530
34. Rostom S, Benbouaaza K, Amine B et al (2010) Psychometric evaluation of the Moroccan version of the Bath Ankylosing Spondylitis Functional Index (BASFI) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in patients with ankylosing spondylitis. Clin Rheumatol 29:781-788
35. Pavy S, Dernis E, Lavie F et al (2007) Imaging for the diagnosis and follow-up of ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion. Joint Bone Spine 74:338-345
36. Braun J, van den Berg R, Baraliakos X et al (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70:896-904
37. Sieper J, Rudwaleit M, Baraliakos X et al (2009) The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68:ii1-ii44
38. van den Berg R, Baraliakos X, Braun J, van der Heijde D (2012) First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and nonbiologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology (Oxford) 51(8):1388-1396
39. Badsha H, Tak PP (2008) Can Islamic prayers benefit spondyloarthritides? Case report of a patient with ankylosing spondylitis and increased spinal mobility after an intensive regimen of Islamic prayer. Rheumatol Int 28:1057-1059
40. Alnaqbi KA, Haroon N, Shen H, Cook RJ, Carty A, Inman R (2011) Profiling NSAID responders in ankylosing spondylitis [abstract]. Arthritis Rheum 63:1330
41. Wanders A, Heijde D, Landewe R et al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52:1756-1765
42. Braun J, Davis J, Dougados M et al (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65:316-320
43. Braun J, Zochling J, Baraliakos X et al (2006) Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 65:1147-1153
44. Dougados M, van der Linden S, Leirisalo-Repo M et al (1995) Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38:618-627
45. Haibel H, Brandt HC, Song IH et al (2007) No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 66:419-421
46. Haibel H, Rudwaleit M, Braun J, Sieper J (2005) Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 64:124-126
47. Braun J, Landewé R, Hermann KG et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54:1646-1652
48. Braun J, Deodhar A, Dijkmans B et al (2008) Efficacy and safety of infliximab in patients with ankylosing spondylitis over a twoyear period. Arthritis Rheum 59:1270-1278
49. Davis JC, van der Heijde DM, Braun J et al (2005) Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64:1557-1562
50. van der Heijde D, Schiff MH, Sieper J et al (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 68:922-929
51. Barkham N, Keen HI, Coates LC et al (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60:946-954
52. Smith R, Cattamanchi A, Steingart KR, Denkinger C, Dheda K, Winthrop KL, Pai M (2011) Interferon-gamma release assays for diagnosis of latent tuberculosis infection: evidence in immunemediated inflammatory disorders. Curr Opin Rheumatol 23:377-384